Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
WHO compiles a list of antibacterials in clinical development on a regular basis, the last in mid-2024 [1]. The information is up-to-date and detailed: it provides MoA and antibacterial spectrum, coverage of problem pathogens, the development phase, and whether it Continue reading A Critical Review of WHO’s List of Antibacterials in Clinical Development
Besides ceftriaxone (CTRIAX), cefixime and spectinomycin we have no other highly effective single-dose treatment regimens for urogenital GC. Failures of all 3 drugs have been described but remain rare, can be overcome with higher doses of CTRIAX (1 g instead Continue reading GC Therapy – Shooting for the Stars
According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That Continue reading QIDP Drug Update – Part 2: Categories of Interest
At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug